This article is more than 5 years old. Information may no longer be current.
Santen reports interim results with two new glaucoma drugs
Click Here to Manage Email Alerts
Preliminary results from clinical trials of two glaucoma drug candidates, an angiotensin-2 receptor antagonist and a prostaglandin derivative, have shown mixed results, Santen Pharmaceuticals said in a press release.
An early phase 2 study of DE-092, also known as olmesartan, in the United States indicated “some IOP reduction,” the company said, but the efficacy was insufficient, and no clear dose-response relationship was seen among the various concentrations. Santen is considering another dose-response study and may reposition DE-092 in the United States and Europe after the Japanese phase 2 results are available, the release said. Santen is conducting a late phase 2 trial of the compound in Japan.
A phase 3 trial of DE-085, also known as tafluprost, in Europe has “demonstrated DE-085’s strong IOP-lowering effect as expected for prostaglandins, but the drug did not demonstrate non-inferiority to latanoprost for the primary endpoint,” the company said. The study is ongoing, and Santen plans to conduct a detailed analysis once final results are available.